ArticleClinical reviews in allergy & immunology
Current issues with beta2-adrenoceptor agonists: historical background.
Article in Clinical reviews in allergy & immunology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 7 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 7 syntheses or guidelines pooled it, 43 citations in OpenAlex.
- Stopping long-acting beta2-agonists (LABA) for adults with asthma well controlled by LABA and inhaled corticosteroids.The Cochrane database of systematic reviews · 2015Pooled it
- Stopping long-acting beta2-agonists (LABA) for children with asthma well controlled on LABA and inhaled corticosteroids.The Cochrane database of systematic reviews · 2015Pooled it
- Safety of regular formoterol or salmeterol in adults with asthma: an overview of Cochrane reviews.The Cochrane database of systematic reviews · 2014Pooled it
- Pooled it
- Safety of regular formoterol or salmeterol in children with asthma: an overview of Cochrane reviews.The Cochrane database of systematic reviews · 2012Pooled it
- Regular treatment with formoterol for chronic asthma: serious adverse events.The Cochrane database of systematic reviews · 2012Pooled it
- Regular treatment with salmeterol for chronic asthma: serious adverse events.The Cochrane database of systematic reviews · 2008Pooled it
- Review
- Asthma and COPD: A Focus on β-Agonists - Past, Present and Future.Handbook of experimental pharmacology · 2024Review
- β2-Adrenoreceptor Agonists, Montelukast, and Parkinson Disease Risk.Annals of neurology · 2023Article
- Understanding how long-acting βBritish journal of pharmacology · 2016Review
- Inhaled βBreathe (Sheffield, England) · 2016Article
- The antidiabetic agent glibenclamide protects airway hyperresponsiveness and inflammation in mice.Inflammation · 2015Article
- β2-Adrenoceptor agonists are required for development of the asthma phenotype in a murine model.American journal of respiratory cell and molecular biology · 2013Article
- A Selective Pharmacophore Model for beta(2)-Adrenoceptor Agonists.Molecules (Basel, Switzerland) · 2009Article
- Vasculitis: current status and future directions.Clinical reviews in allergy & immunology · 2008Article
- Cutting edge issues in autoimmunity.Clinical reviews in allergy & immunology · 2008Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The discovery that dessicated adrenal glands had beneficial effects in asthma arose in 1900 following a vogue for studying organotherapy at the end of the 19th century. The adrenal hormone adrenaline was found to have sympathomimetic properties and was isolated and synthesized in 1901. The first nonselective beta-agonist, isoproterenol, was isolated in 1940, followed by the development of selective beta2-agonists in the 1960s and the introduction of the long-acting beta2-agonists in the 1990s. The introduction of beta2-selectivity reduced adverse effects, as did developments in inhaler technology that allowed subjects to inhale much smaller doses of drug selectively to the airways. The beta2-agonists are some of the more important drugs to have been developed in the 20th century. Excessive doses can cause problems, and attempts to maximize the benefit from beta2-agonists and to reduce adverse effects has led to considerable epidemiological, clinical, and mechanistic research over the last 50 yr.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.